ÌÇÐÄ´«Ã½

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

Trial ID or NCT#

NCT05862012

Status

recruiting iconRECRUITING

Purpose

This study is a first-in-human, Phase 1, open-label study that will evaluate safety and anti-myeloma activity of ISB 2001 in participants with relapsed/refractory multiple myeloma (R/R MM).

Official Title

A Phase 1, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 2001 in Subjects With Relapsed/Refractory Multiple Myeloma

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Michaela Liedtke
Michaela Liedtke
Hematologist-Oncologist
CKD Family Professor

Contact us to find out if this trial is right for you.

Contact

Caitlyn Minas
650-723-0646

SEND MESSAGE

View on